Post by marriott on Aug 6, 2021 18:30:06 GMT
So yesterday's call is now part of the Novavax story .
Let's explore the true nature of today's dramatic fall in the share price and Novavax's forward developments .
We learned that Novavax , in partnership with SII , filed submissions for EUA in India , Indonesia and the Philippines . In addition , finalized APA with EC ,
no At-the-Market (ATM) offerings during the quarter , moving to achieve 100 million dose monthly capacity by the end of the third quarter and 150 million dose monthly capacity by the end of the fourth quarter , and as of June 30, 2021, Novavax had $2.1 billion in cash and equivalents .
Kudos to the Novavax team .
And then , the statement that the company would submit EUA to U.S. FDA " in the fourth quarter " . And of course , the media focused on this announcement and expected resistance followed.
And , of course for many here , CEO Erck was the fall guy !
Longs' know painfully well the history of Novavax and we are reminded constantly that the company has no vaccines in the commercial market.
Now with the filings in India , Indonesia and the Philippines , Novavax has a real chance to remove " no vaccines in the commercial market " from its
identity and brand .
Going back to the achievements stated during the call, the market knows that the labor power and financial resources required will be substantial .
The market , being a forward looking beast, thinks of the resources and effort involved in the EUA filing with FDA . Of course, Novavax is saddled with
the " delays " associated with various projected manufacturing activities.
In my opinion , the missing link associated with the Novavax story at the present time is the belief that the EUA filing in the US will be further delayed beyond the fourth quarter because the perception that company may not have the production resources, personnel and management expertise to fulfill ALL of its ongoing projects.
The antidote will be when just one of the EUAs filed submissions is approved , the statement that the company has " no vaccines in the commercial market " will no longer apply and this will usher a new market focus on forward developments. Valuations and projections will carry more weight because they will be based on real earnings and projections.
Personal note - I have taken 2373 with absolutely no adverse effects .
I believe Novavax will shine and truly help people in need throughout the global community ,
Long live Novavax and all true longs !!!!!
Let's explore the true nature of today's dramatic fall in the share price and Novavax's forward developments .
We learned that Novavax , in partnership with SII , filed submissions for EUA in India , Indonesia and the Philippines . In addition , finalized APA with EC ,
no At-the-Market (ATM) offerings during the quarter , moving to achieve 100 million dose monthly capacity by the end of the third quarter and 150 million dose monthly capacity by the end of the fourth quarter , and as of June 30, 2021, Novavax had $2.1 billion in cash and equivalents .
Kudos to the Novavax team .
And then , the statement that the company would submit EUA to U.S. FDA " in the fourth quarter " . And of course , the media focused on this announcement and expected resistance followed.
And , of course for many here , CEO Erck was the fall guy !
Longs' know painfully well the history of Novavax and we are reminded constantly that the company has no vaccines in the commercial market.
Now with the filings in India , Indonesia and the Philippines , Novavax has a real chance to remove " no vaccines in the commercial market " from its
identity and brand .
Going back to the achievements stated during the call, the market knows that the labor power and financial resources required will be substantial .
The market , being a forward looking beast, thinks of the resources and effort involved in the EUA filing with FDA . Of course, Novavax is saddled with
the " delays " associated with various projected manufacturing activities.
In my opinion , the missing link associated with the Novavax story at the present time is the belief that the EUA filing in the US will be further delayed beyond the fourth quarter because the perception that company may not have the production resources, personnel and management expertise to fulfill ALL of its ongoing projects.
The antidote will be when just one of the EUAs filed submissions is approved , the statement that the company has " no vaccines in the commercial market " will no longer apply and this will usher a new market focus on forward developments. Valuations and projections will carry more weight because they will be based on real earnings and projections.
Personal note - I have taken 2373 with absolutely no adverse effects .
I believe Novavax will shine and truly help people in need throughout the global community ,
Long live Novavax and all true longs !!!!!